Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) - Total Liabilities
Based on the latest financial reports, Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) has total liabilities worth CN¥3.56 Billion CNY (≈ $520.34 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Sinopep-Allsino Biopharmaceutical Co. Lt (688076) cash flow conversion to assess how effectively this company generates cash.
Sinopep-Allsino Biopharmaceutical Co. Ltd. A - Total Liabilities Trend (2013–2024)
This chart illustrates how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Sinopep-Allsino Biopharmaceutical Co. Lt to evaluate the company's liquid asset resilience ratio.
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Sinopep-Allsino Biopharmaceutical Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
O-I Glass Inc
NYSE:OI
|
USA | $6.93 Billion |
|
LS Materials
KQ:417200
|
Korea | ₩85.47 Billion |
|
Suzhou Hailu Heavy Industry Co Ltd
SHE:002255
|
China | CN¥2.25 Billion |
|
Black Box Limited
NSE:BBOX
|
India | Rs26.34 Billion |
|
Concord Biotech Limited
NSE:CONCORDBIO
|
India | Rs1.96 Billion |
|
Kelt Exploration Ltd.
TO:KEL
|
Canada | CA$477.39 Million |
|
Happy Forgings Limited
NSE:HAPPYFORGE
|
India | Rs3.41 Billion |
|
Enovis Corp
NYSE:ENOV
|
USA | $2.34 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Sinopep-Allsino Biopharmaceutical Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 688076 market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sinopep-Allsino Biopharmaceutical Co. Ltd. A (2013–2024)
The table below shows the annual total liabilities of Sinopep-Allsino Biopharmaceutical Co. Ltd. A from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.40 Billion ≈ $350.57 Million |
+76.42% |
| 2023-12-31 | CN¥1.36 Billion ≈ $198.71 Million |
+127.30% |
| 2022-12-31 | CN¥597.41 Million ≈ $87.42 Million |
+87.78% |
| 2021-12-31 | CN¥318.14 Million ≈ $46.55 Million |
-25.94% |
| 2020-12-31 | CN¥429.55 Million ≈ $62.86 Million |
+5.92% |
| 2019-12-31 | CN¥405.54 Million ≈ $59.34 Million |
+52.76% |
| 2018-12-31 | CN¥265.47 Million ≈ $38.85 Million |
-8.55% |
| 2017-12-31 | CN¥290.27 Million ≈ $42.48 Million |
+131.92% |
| 2016-12-31 | CN¥125.16 Million ≈ $18.31 Million |
+1.46% |
| 2015-12-31 | CN¥123.35 Million ≈ $18.05 Million |
-28.72% |
| 2014-12-31 | CN¥173.05 Million ≈ $25.32 Million |
+6.09% |
| 2013-12-31 | CN¥163.12 Million ≈ $23.87 Million |
-- |
About Sinopep-Allsino Biopharmaceutical Co. Ltd. A
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers Peptide CDMO Services,GMP oligo, full-time equivalent, discovery, generic APIs, and formulation services. It is also involved in professional technical services. The company was… Read more